San Francisco startup Composition Therapeutics is usually working on an oral, after-everyday GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s anticipations in June when a mid-phase study showed regular weight loss of close to 6% and it plans to start Yet another mid-phase